| V0 | V1 | V2 | V3 | V4 | V5 | V6 | V7 | V8 | V9 | Survival- Follow-up |
Demography | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Medical history | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Oncological history | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Tumor classification | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Pregnancy test1 | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Inclusion / Exclusion | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Laboratory | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Biopsy | X | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Randomisation | Â | X | Â | Â | Â | Â | Â | Â | Â | Â | Â |
Physical examination | X | Â | X | X | X | X | X | X | X | X | Â |
Anamnesis | X | Â | Â | X | X | X | X | X | X | X | Â |
Endoscopy | X | Â | Â | Â | X2 | X2 | X2 | X2 | X2 | X2 | Â |
CT/MRI | X | Â | Â | Â | X2 | X2 | X2 | X2 | X2 | X2 | Â |
Concomitant Medication | X | Â | X | X | X | X | X | X | X | X | Â |
EORTC QLQ-C30, −STO22, −OG 25- |  | X | X |  | X | X | X | X | X | X |  |
OP – Description |  |  | X |  |  |  |  |  |  |  |  |
Post-OP Complication | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â |
Pathology | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â |
Reference pathology | Â | Â | X | Â | Â | Â | Â | Â | Â | Â | Â |
AE/SAE | Â | Â | X | X | X | Â | Â | Â | Â | Â | Â |
Survival | Â | Â | Â | X | X | X | X | X | X | X | X |
EOS | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | or earlier for premature withdrawal |